For an individual confirmed to carry a BRCA1 mutation, a structured, lifelong surveillance plan should be established in coordination with a clinical geneticist, oncologist, and gynaecologist, since the elevated risk applies to multiple organ systems and not breast tissue alone.

*For breast cancer surveillance, clinical breast examination should be performed every six to twelve months starting at age twenty-five, alongside annual breast magnetic resonance imaging beginning at age twenty-five, with annual mammography added from age thirty onward, and both imaging modalities are typically alternated every six months so that the breast tissue is monitored twice a year in total.
*Breast self-awareness training should also be provided so that any new lump, skin change, or nipple discharge is reported promptly rather than waiting for the next scheduled screening.
*For ovarian cancer, routine screening using transvaginal ultrasound and the blood marker cancer antigen 125 has not been shown to reliably detect ovarian cancer at an early stage, so the primary proactive step recommended is risk-reducing bilateral salpingo-oophorectomy between the ages of thirty-five and forty or after childbearing is complete, this window being earlier than for BRCA2 carriers because BRCA1 mutations are associated with a higher and earlier-onset lifetime ovarian cancer risk, since no effective early detection tool currently exists for this cancer type. *Pancreatic cancer surveillance is not routinely recommended for BRCA1 carriers, since the association between BRCA1 mutations and pancreatic cancer risk is weaker and less consistently established compared to BRCA2, though individuals with a strong family history of pancreatic cancer specifically should still discuss surveillance options with a specialist.
*Men who carry a BRCA1 mutation have a smaller increase in prostate cancer risk compared to BRCA2 carriers, so prostate-specific antigen based prostate cancer screening is generally discussed from around age forty-five, in line with general moderate-risk guidance, though this should be individualised based on family history.
*Skin examinations for melanoma should still be discussed with a dermatologist, though the association with BRCA1 is not strongly established. Alongside clinical surveillance, lifestyle measures that support overall risk reduction include maintaining a healthy body weight, limiting alcohol consumption, avoiding tobacco use, and staying physically active, since these factors influence overall cancer risk even though they do not eliminate the genetic risk itself.
*Finally, genetic counseling should be revisited periodically, since surveillance guidelines are updated as research evolves, and family planning discussions, including options such as preimplantation genetic testing, should be raised with a fertility specialist if the individual is considering having children.